Literature DB >> 31113231

Center Predictors of Long-Term Benzodiazepine Use in Chronic Obstructive Pulmonary Disease and Post-traumatic Stress Disorder.

Lucas M Donovan1,2, Carol A Malte1, Laura J Spece1,2, Matthew F Griffith1,2, Laura C Feemster1,2, Steven B Zeliadt1,3, David H Au1,2, Eric J Hawkins1,4.   

Abstract

Rationale: Symptoms of insomnia and anxiety are common among patients with chronic obstructive pulmonary disease (COPD), especially among patients with comorbid mental health disorders such as post-traumatic stress disorder (PTSD). Benzodiazepines provide temporary relief of these symptoms, but guidelines discourage routine use of benzodiazepines because of the serious risks posed by these medications. A more thorough understanding of guideline-discordant benzodiazepine use will be critical to reduce potentially inappropriate prescribing and its associated risks.
Objectives: Examine the national prevalence, variability, and center correlates of long-term benzodiazepine prescriptions for patients with COPD and comorbid PTSD.
Methods: We identified patients with COPD and PTSD between 2010 and 2012 who received care within the Department of Veterans Affairs. We used a mixed-effects logistic regression model to assess center predictors of long-term benzodiazepine prescriptions (≥90 d), while accounting for patient characteristics.
Results: Of 43,979 patients diagnosed with COPD and PTSD at 129 centers, 24.4% were prescribed benzodiazepines long term, with use varying from 9.5% to 49.4% by medical center. Patients with long-term prescriptions were more likely to be white (90.1% vs. 80.7%) and have other mental health comorbidities, including generalized anxiety disorder (31.3% vs. 16.5%). Accounting for patient mix and characteristics, long-term benzodiazepine use was associated with lower patient-reported access to mental health care (odds ratio, 0.54; 95% confidence interval, 0.37-0.80).Conclusions: Long-term benzodiazepine prescribing is common among patients at high risk for complications, although this practice varies substantially from center to center. Poor access to mental health care is a potential driver of this guideline inconsistent use.

Entities:  

Keywords:  benzodiazepines; chronic obstructive pulmonary disease; post-traumatic stress disorder

Year:  2019        PMID: 31113231      PMCID: PMC6812159          DOI: 10.1513/AnnalsATS.201901-048OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  53 in total

Review 1.  The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia.

Authors:  Jaime M Monti; Pablo Torterolo; Seithikurippu R Pandi Perumal
Journal:  Sleep Med Rev       Date:  2016-05-15       Impact factor: 11.609

2.  Controlled discontinuation of benzodiazepine treatment for patients with panic disorder.

Authors:  R Noyes; M J Garvey; B Cook; M Suelzer
Journal:  Am J Psychiatry       Date:  1991-04       Impact factor: 18.112

3.  Chronic posttraumatic stress disorder and chronic pain in Vietnam combat veterans.

Authors:  J C Beckham; A L Crawford; M E Feldman; A C Kirby; M A Hertzberg; J R Davidson; S D Moore
Journal:  J Psychosom Res       Date:  1997-10       Impact factor: 3.006

4.  Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study.

Authors:  William V Bobo; Noreen A Reilly-Harrington; Terence A Ketter; Benjamin D Brody; Gustavo Kinrys; David E Kemp; Richard C Shelton; Susan L McElroy; Louisa G Sylvia; James H Kocsis; Melvin G McInnis; Edward S Friedman; Vivek Singh; Mauricio Tohen; Charles L Bowden; Thilo Deckersbach; Joseph R Calabrese; Michael E Thase; Andrew A Nierenberg; Dustin J Rabideau; David A Schoenfeld; Stephen V Faraone; Masoud Kamali
Journal:  J Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.153

Review 5.  REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.

Authors:  Erik K St Louis; Angelica R Boeve; Bradley F Boeve
Journal:  Mov Disord       Date:  2017-05       Impact factor: 10.338

6.  Non-benzodiazepines for the treatment of insomnia.

Authors:  Judy Wagner; Mary L. Wagner
Journal:  Sleep Med Rev       Date:  2000-12       Impact factor: 11.609

7.  Benzodiazepine use among depressed patients treated in mental health settings.

Authors:  Marcia Valenstein; Kiran Khanujua Taylor; Karen Austin; Helen C Kales; John F McCarthy; Frederic C Blow
Journal:  Am J Psychiatry       Date:  2004-04       Impact factor: 18.112

8.  Risks of Benzodiazepines in Chronic Obstructive Pulmonary Disease with Comorbid Posttraumatic Stress Disorder.

Authors:  Lucas M Donovan; Carol A Malte; Laura J Spece; Matthew F Griffith; Laura C Feemster; Ruth A Engelberg; David H Au; Eric J Hawkins
Journal:  Ann Am Thorac Soc       Date:  2019-01

9.  "Those Conversations in My Experience Don't Go Well": A Qualitative Study of Primary Care Provider Experiences Tapering Long-term Opioid Medications.

Authors:  Laura C Kennedy; Ingrid A Binswanger; Shane R Mueller; Cari Levy; Daniel D Matlock; Susan L Calcaterra; Stephen Koester; Joseph W Frank
Journal:  Pain Med       Date:  2018-11-01       Impact factor: 3.750

10.  Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study.

Authors:  Magnus P Ekström; Anna Bornefalk-Hermansson; Amy P Abernethy; David C Currow
Journal:  BMJ       Date:  2014-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.